Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Acura's NDA for Acurox accepted by FDA for filing with priority review

March 5, 2009

Immunomodulation via Toll-like receptors may be beneficial in Alzheimer's disease

March 5, 2009

FDA approves Copaxone for patients with a first clinical event of MS

March 5, 2009

Sonexa Therapeutics evaluates efficacy and safety of ST-101 in Alzheimer's disease

March 5, 2009

Astellas terminates ASP-2314/ACR-16 license agreement with Neurosearch

March 4, 2009

Zonisamide reduces tremor scores in patients with essential tremor

March 4, 2009

Taisho scientists present new antidepressive NMU2 ligands

March 4, 2009

Intellect Neurosciences' AD candidate Oxigon reported to have copper-binding properties

March 4, 2009

Marinus presents successful results from phase II ganaxolone trial

March 3, 2009

Endo licenses axomadol and returns rights to Transdur-sufentanil

March 3, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...